Lexaria Bioscience (LEXX) Cash from Operations (2010 - 2026)
Lexaria Bioscience (LEXX) posted Cash from Operations of 1635020.0 for Q2 2026, up 24.44% sequentially from 2163872.0 in Q1 2026, and up 54.38% YoY from 1059091.92 in Q2 2025.
Lexaria Bioscience (LEXX) Cash from Operations (2010 - 2026) Analysis & Trends
Lexaria Bioscience has reported Cash from Operations for 17 years, with the latest figure at 1635020.0 in Q2 2026.
- Quarterly Cash from Operations rose 54.38% year-over-year to 1635020.0 in Q2 2026, while the trailing twelve-month figure through May 2026 was 7425488.0 (up 23.45% YoY) and the FY2025 annual result came in at 10450387.0, down 110.74% from the prior year.
- Cash from Operations advanced to 1635020.0 in Q2 2026 per LEXX's latest filing, from 2163872.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 619614.0 in Q1 2024 and troughed at 3583953.0 in Q2 2025.
- A 5-year average of 1654812.89 and a median of 1387580.5 in 2022 frame the typical range for Cash from Operations.
- The widest YoY moves for Cash from Operations: up 63.9% in 2025, down 183.08% in 2025.
- Over 5 years, Cash from Operations stood at 1245313.0 in 2022, then grew by 5.11% to 1181653.0 in 2023, then tumbled by 130.7% to 2726045.0 in 2024, then soared by 63.9% to 984098.0 in 2025, then slumped by 66.14% to 1635020.0 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 1635020.0, 2163872.0, and 984098.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Lexaria Bioscience | 10.15 Mn | 6.54 Mn | - | -1.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2026 | -1.64 Mn |
| May 31, 2026 | -1.64 Mn |
| Feb 28, 2026 | -2.16 Mn |
| Feb 28, 2026 | -2.16 Mn |
| Nov 30, 2025 | -984,098.00 |
| Nov 30, 2025 | -984,098.00 |
| Aug 31, 2025 | -2.64 Mn |
| Aug 31, 2025 | -2.64 Mn |
| May 31, 2025 | -3.58 Mn |
| May 31, 2025 | -3.58 Mn |
| Feb 28, 2025 | -1.50 Mn |
| Feb 28, 2025 | -1.50 Mn |
| Nov 30, 2024 | -2.73 Mn |
| Nov 30, 2024 | -2.73 Mn |
| Aug 31, 2024 | -1.89 Mn |
| Aug 31, 2024 | -1.89 Mn |
| May 31, 2024 | -1.27 Mn |
| May 31, 2024 | -1.27 Mn |
| Feb 29, 2024 | -619,614.00 |
| Feb 29, 2024 | -619,614.00 |